The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

The results of a study that identified the pathological mechanism of spinal stenosis and the target gene for treatment ...

Professor Zeng Zexian's team from the Center for Quantitative Biology at the Peking University Academy for Advanced Interdisciplinary Studies, in collaboration with the Peking University-Tsinghua ...

Maria Sokolova, head of the Lise Meitner Research Group Bacteriophages at the Max Planck Institute of Biochemistry, receives ...

All future theatre constructions would adhere to this policy. This will ensure a uniform approach to theatre development ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Biology — the science of life, living things and the processes that keep us all running — links up in essential ways with ...

There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells ...

The Memorandum of Understanding (MoU) was signed in the presence of Maharashtra Chief Minister Devendra Fadnavis and his ...

Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...